

basis, of an American Nanotechnology Preparedness Center which shall—

(1) conduct, coordinate, collect, and disseminate studies on the societal, ethical, environmental, educational, legal, and workforce implications of nanotechnology; and

(2) identify anticipated issues related to the responsible research, development, and application of nanotechnology, as well as provide recommendations for preventing or addressing such issues.

**(b) Center for nanomaterials manufacturing**

The Program shall provide for the establishment, on a merit reviewed and competitive basis, of a center to—

(1) encourage, conduct, coordinate, commission, collect, and disseminate research on new manufacturing technologies for materials, devices, and systems with new combinations of characteristics, such as, but not limited to, strength, toughness, density, conductivity, flame resistance, and membrane separation characteristics; and

(2) develop mechanisms to transfer such manufacturing technologies to United States industries.

**(c) Reports**

The Council, through the Director of the National Nanotechnology Coordination Office, shall submit to the Senate Committee on Commerce, Science, and Transportation and the House of Representatives Committee on Science—

(1) within 6 months after December 3, 2003, a report identifying which agency shall be the lead agency and which other agencies, if any, will be responsible for establishing the Centers described in this section; and

(2) within 18 months after December 3, 2003, a report describing how the Centers described in this section have been established.

(Pub. L. 108–153, §9, Dec. 3, 2003, 117 Stat. 1930.)

CHANGE OF NAME

Committee on Science of House of Representatives changed to Committee on Science and Technology of House of Representatives by House Resolution No. 6, One Hundred Tenth Congress, Jan. 5, 2007. Committee on Science and Technology of House of Representatives changed to Committee on Science, Space, and Technology of House of Representatives by House Resolution No. 5, One Hundred Twelfth Congress, Jan. 5, 2011.

**§ 7509. Definitions**

In this chapter:

**(1) Advisory Panel**

The term “Advisory Panel” means the President’s National Nanotechnology Advisory Panel established or designated under section 7503 of this title.

**(2) Nanotechnology**

The term “nanotechnology” means the science and technology that will enable one to understand, measure, manipulate, and manufacture at the atomic, molecular, and supramolecular levels, aimed at creating materials, devices, and systems with fundamentally new molecular organization, properties, and functions.

**(3) Program**

The term “Program” means the National Nanotechnology Program established under section 7501 of this title.

**(4) Council**

The term “Council” means the National Science and Technology Council or an appropriate subgroup designated by the Council under section 7501(c) of this title.

**(5) Advanced technology user facility**

The term “advanced technology user facility” means a nanotechnology research and development facility supported, in whole or in part, by Federal funds that is open to all United States researchers on a competitive, merit-reviewed basis.

**(6) Program component area**

The term “program component area” means a major subject area established under section 7501(c)(2) of this title under which is<sup>1</sup> grouped related individual projects and activities carried out under the Program.

(Pub. L. 108–153, §10, Dec. 3, 2003, 117 Stat. 1931.)

**CHAPTER 102—FAIRNESS TO CONTACT LENS CONSUMERS**

Sec.	
7601.	Availability of contact lens prescriptions to patients.
7602.	Immediate payment of fees in limited circumstances.
7603.	Prescriber verification.
7604.	Expiration of contact lens prescriptions.
7605.	Content of advertisements and other representations.
7606.	Prohibition of certain waivers.
7607.	Rulemaking by Federal Trade Commission.
7608.	Violations.
7609.	Study and report.
7610.	Definitions.

**§ 7601. Availability of contact lens prescriptions to patients**

**(a) In general**

When a prescriber completes a contact lens fitting, the prescriber—

(1) whether or not requested by the patient, shall provide to the patient a copy of the contact lens prescription; and

(2) shall, as directed by any person designated to act on behalf of the patient, provide or verify the contact lens prescription by electronic or other means.

**(b) Limitations**

A prescriber may not—

(1) require purchase of contact lenses from the prescriber or from another person as a condition of providing a copy of a prescription under subsection (a)(1) or (a)(2) or verification of a prescription under subsection (a)(2);

(2) require payment in addition to, or as part of, the fee for an eye examination, fitting, and evaluation as a condition of providing a copy of a prescription under subsection (a)(1) or (a)(2) or verification of a prescription under subsection (a)(2); or

<sup>1</sup> So in original. Probably should be “are”.